Abstract Organs-on-chips (OoCs), also known as microphysiological systems or 'tissue
chips'(the terms are synonymous), have attracted substantial interest in recent years owing …

Predicting the effects of drugs before human clinical trials is at the heart of drug screening
and discovery processes. The cost of drug discovery is steadily increasing owing to the …

The cell microenvironment has emerged as a key determinant of cell behavior and function
in development, physiology, and pathophysiology. The extracellular matrix (ECM) within the …

Organs-on-a-chip (OOCs) are miniature tissues and organs grown in vitro that enable
modeling of human physiology and disease. The technology has emerged from converging …

Significant advances in materials, microscale technology, and stem cell biology have
enabled the construction of 3D tissues and organs, which will ultimately lead to more …

Organ-on-a-chip (OOAC) is an emerging technology based on microfluid platforms and in
vitro cell culture that has a promising future in the healthcare industry. The numerous …

Current in-vitro 2D cultures and animal models present severe limitations in recapitulating
human physiopathology with striking discrepancies in estimating drug efficacy and side …

Organ-on-a-chip devices have enabled major breakthroughs in biomedical research, but
they have yet to be successfully translated to the pharmaceutical industry. Traditional …

Abstract Treatment and management of kidney disease currently presents an enormous
global burden, and the application of nanotechnology principles to renal disease therapy …

Diabetic nephropathy is a major chronic renal complication of diabetes mellitus, and is the
leading cause of end-stage kidney diseases. Establishing a disease model of diabetic …